Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study

• Príomhchruthaitheoirí: Ying Li (Údar), Chengzhi Lv (Údar), Lin Dang (Údar), Bingjiang Lin (Údar), Juan Tao (Údar), Chunlei Zhang (Údar), Xiaoyong Zhou (Údar), Han Ma (Údar), Yi Lu (Údar), Rong Chen (Údar), Jinnan Li (Údar), Guanshen Dou (Údar), Yunsheng Liang (Údar), Yanhua Liang (Údar), Yuling Shi (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Adis, Springer Healthcare, 2024-03-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Abstract Introduction Ixekizumab, a monoclonal antibody against interleukin-17A, demonstrated effectiveness in the treatment of psoriasis in a Chinese real-world study that was consistent with previous randomized controlled trials. Here, we report further analyses from this study to explore the effe...